Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib QTc interval study in healthy volunteers
NCT05630274Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2019
- Primary completion
- Jun 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selpercatinib (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction at 24 hours, Area Under the Concentration-time Curve From Time 0 to the Time of the Last Observed Non-zero Concentration at 240 hours and 6 more. Started Apr 2019; status: completed.
02
Drugs
selpercatinib
Beyond the preview
Go deeper on NCT05630274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630274.